Abstract： Objective： To analyze the active components and mechanism of action of Stigma Maydis in treating hypertension based on network pharmacology and molecular docking technology. Methods： The main active components and corresponding targets of Stigma Maydis were collected from the TCMSP database and the Swiss Target Prediction database. Hypertension-related target genes were searched in GeneCards and OMIM， and the common targets of components and diseases were obtained using the VENNY2.1 platform. The "active component - intersection target" network was constructed using Cytoscape3.9.1 software. The PPI network was constructed using the STRING database and Cytoscape3.9.1 software， and the core targets were screened. GO and KEGG functional enrichment analyses were performed using the DAVID database，and finally molecular docking was conducted. Results：A total of 11 active components， 457 active component targets， 5 263 disease targets， and 313 intersection targets of active component targets and disease targets were obtained. The main active components of Stigma Maydis in treating hypertension may be α -tocopherylquinone， stigmasta-4， 22-diene-3β， 6β-diol， stigma-4-en-3， and 6-diol， etc. The core targets were AKT serine/threonine kinase 1（AKT1）， tumor necrosis factor （TNF）， and interleukin 6 （IL-6）. The GO enrichment analysis results showed that biological processes are primarily involved in the epidermal growth factor receptor signaling pathway， cellular components mainly involve the plasma membrane and receptor complexes， and molecular functions are primarily associated with histone H2AX-Y142 kinase activity. KEGG enrichment analysis indicated associations with pathways such as neuroactive ligand-receptor interactions calcium，and advanced glycation end produt and its receptor （AGE-RAGE） pathways. Molecular docking results demonstrated that the core components exhibited favorable binding with the target proteins. Conclusion： Stigma Maydis may exert its therapeutic effect on hypertension through components such as α-tocopherylquinone，stigmasta-4，22-diene-3β，6β- diol，stigma-4-en-3，and 6-diol. These components act on targets including AKT1，TNF，and IL-6，and regulate pathways like neuroactive ligand-receptor interaction calcium，and AGE-RAGE pathways to achieve this effect.